Lexaria Awards Contract For Third GLP-1 Human Pilot Study [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
KELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization (" CRO ") to perform the Company's human pilot study #3, (the " Study ") which will evaluate a dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulintropic peptide). The Study will be a randomized, crossover investigation that will compare injected tirzepatide (Zepbound® by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound® and rendered into a capsule to be swallowed. There are two study arms: DehydraTECH-tirzepatide swallowed capsules; and, Injected Zepbound® tirzepatide by Eli Lilly. Tirzepatide is currently available only in its injected form, Zepbound®, by Eli Lilly - it is not available in an FDA-approved oral dosage format. The Study will evaluate whether DehydraTECH-processed tirzepat
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study [Yahoo! Finance]Yahoo! Finance
- Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human StudyAccesswire
- Dosing Continues in Lexaria’s Second GLP-1 Human Pilot StudyAccesswire
- Lexaria Awards Contract For Third GLP-1 Human Pilot StudyAccesswire
- Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy [Yahoo! Finance]Yahoo! Finance
LEXX
Sec Filings
- 6/12/24 - Form EFFECT
- 6/11/24 - Form 424B3
- 6/3/24 - Form S-1
- LEXX's page on the SEC website